Drugs / RBP-6000
RBP-6000
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02559973 | Sep 2015 → Feb 2016 | substance-related disorder | Indivior Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03002961 | Jul 2012 → Feb 2013 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01738503 | Oct 2012 → May 2014 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT03809143 | May 2019 → Nov 2020 | opiate dependence | The University of New South Wales | Unknown | No outcome recorded |
| Phase 3 | NCT02896296 | Aug 2016 → Aug 2017 | substance-related disorder | Indivior Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02510014 | Jul 2015 → Jan 2017 | substance-related disorder | Indivior Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02357901 | Jan 2015 → Apr 2016 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBP-6000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02559973 ↗ |
| Known as | BPN | “RBP-6000 (BPN in the ATRIGEL® Delivery System) contains buprenorphine (200mg/mL) in the ATRIGEL® Delivery System, which provides sustained plasma level of BPN over a minimum of 28 days.” NCT03809143 ↗ |
| Known as | BUP-XR | “RBP-6000, referred to as BUP-XR (extended-release buprenorphine), is a subcutaneously injected, monthly buprenorphine treatment for opioid use disorder.” PMID 30792007 ↗ Feb 2019 |
| Known as | Depot Buprenorphine | “A Multicenter, Open-Label, Single Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Depot Buprenorphine (RBP-6000) in Opioid-Dependent Subjects” NCT03002961 ↗ |
| Route | Subcutaneous | “subcutaneous (SC) injection using the ATRIGEL® Delivery System” NCT01738503 ↗ |